Prostate Cancer
Conditions
Brief summary
The aim of this project is to determine whether androgen deprivation therapy (ADT) decreases left ventricular function in prostate cancer patients. If found successful, this may lead to improved cardiovascular health via treatment and/or lifestyle interventions in prostate cancer populations.
Detailed description
Prostate Cancer is the second most common cancer among American men. Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime. In prostate cancer patients alone, hypotestosteronemia, caused by prostate cancer treatment is associated with visceral adiposity, insulin resistance, metabolic syndrome, decreased high-density lipoprotein, increased low-density lipoprotein, increased triglycerides, loss of muscle mass, erectile disfunction, and a loss of microvascular endothelial function. Recently, several population-based studies have reported an association between androgen deprivation therapy and an increased risk of cardiovascular events, that include myocardial infarction and cardiovascular mortality. Given this link and the growing evidence that androgen-deprivation therapy adversely affects traditional risk factors, it is essential to better understand the role this type of treatment has on cardiac structure and function. As such, the manifestation of cardiovascular toxicities with prostate cancer treatment will initially be subclinical (left ventricular function changes in asymptomatic individuals) compared to clinical (including coronary symptoms or heart failure) and may develop subacutely (during treatment) or chronically.
Interventions
DIAGNOSTIC_TESTTransthoracic Echocardiography
Non-invasive assessment of left ventricle structure and function
DIAGNOSTIC_TESTArterial blood pressure
Continuously monitored for 5-30 minutes via finger photoplethysmography
DIAGNOSTIC_TESTSubmaximal Exercise
Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
Sponsors
Kansas State University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
21 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Give voluntary consent to participate in the study * (Group 1) Diagnosed prostate cancer patient/survivor with a history of androgen deprivation therapy treatment * (Group 2) Diagnosed prostate cancer patient/survivor with no history of androgen deprivation therapy treatment * (Group 3) Cancer free
Exclusion criteria
* History of clinical cardiovascular disease (Atherosclerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemia attack (TIA), or peripheral arterial disease presumed to be of atherosclerotic origin) * Not met the above criteria * Unable to provide informed consent * History of smoking (within 6 months) or current smoker * Major signs or symptoms suggestive of cardiovascular, pulmonary, or metabolic disease. These include pain, discomfort in the chest, neck, jaw, arms or other areas that may result form ischemia; shortness of breath at rest or with mild exertion; Dizziness or syncope; Orthopnea or paroxysmal nocturnal dyspnea; ankle edema; palpitations or tachycardia; intermittent claudication; known heart murmur; unusual fatigue or shortness of breath with usual activities
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left ventricular ejection fraction | 1 day | measure of left ventricular systolic function |
| Left ventricular strain rate | 1 day | measure of left ventricular systolic and diastolic function |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac output | 1 day | measure of cardiac function at rest and during submaximal exercise |
Countries
United States
Outcome results
None listed